Bionano’s Optical Genome Mapping for Acute Lymphoblastic Leukemia Subjects at the University Hospitals Leuven, Belgium, Has Faster Turnaround Time, Higher Success Rates and Lower Cost per Sample Compared to Traditional Methods
OGM Benefits | Summary of Findings Presented | |
Faster Turnaround Time | • Turnaround time, for sample to reportable result, went from 4 weeks with traditional methods to only 1 week using OGM | |
Workflow Simplification and Assay Consolodation | • Reduction in the number of cumbersome and expensive FISH experiments from 10 to only 1 per patient, eliminating the use of MLPA and most PCR tests, and reducing the number of samples analyzed via karyotyping | |
Less Hands-On Time | • Significant reduction in hands-on time for laboratory personnel and the time necessary for data analysis using OGM relative to traditional methods | |
Higher Assay Success Rates | • Higher assay success rates versus traditional methods since OGM is performed directly from the sample source, using DNA extraction, without the additional need for laborious cell culture as required for karyotyping | |
Higher Yield of Pathogenic Findings | • 5% of cases yielded additional pathogenic findings using OGM, which would be missed by traditional methods alone | |
Improved Outcomes | • An addiitonal 5% of cases resulted in an improvement in treatment recommendation from enhanced prognostic stratification using OGM relative to traditional methods | |
• Reduction in cost by 50% per sample by using OGM instead of the combination of traditional methods |
In a plenary talk at the
About
Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the significance of Bionano OGM data discussed in this press release, including the potential for such data to lead to improved treatment options, patient stratification, or medical care; Bionano OGM’s superiority in genomic analysis in certain applications as compared to traditional techniques; the benefits of the Saphyr system relative to traditional cytogenetic testing methods; our assessments regarding market opportunities; and the execution of Bionano’s strategy. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the
CONTACTS
Company Contact:
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations and
Media Contact:
+1 (858) 366-3243
amy@juniper-point.com
Source: Bionano Genomics